Cell Therapy Market

Global Cell Therapy Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2023-2029: The market will expand due to the increasing prevalence of chronic and degenerative diseases, advancements in regenerative medicine, and growing personalized medicine approach.

Global Cell Therapy Market is valued at USD 10.48 Billion in 2022 and it is expected to reach USD 31.09 Billion by 2029 with a CAGR of 16.8% over the forecast period.

Scope of Global Cell Therapy Market Report-

Cell therapy is a revolutionary field in medicine that involves the use of living cells to treat, repair, or replace damaged or diseased tissues and organs. It offers promising solutions for various medical conditions that were previously considered incurable. The history of cell therapy can be traced back to the early 20th century when the first successful bone marrow transplant was performed. Since then, significant advancements have been made, particularly in the past few decades, with the discovery of stem cells and their therapeutic potential.

Cell therapy finds applications in a wide range of medical areas, including oncology, cardiovascular diseases, autoimmune disorders, neurodegenerative conditions, and more. For instance, in oncology, immune cells called T cells are genetically modified and infused back into the patient to target and destroy cancer cells. In neurodegenerative disorders like Parkinson's disease, stem cells are used to replace damaged or lost neurons. The versatility of cell therapy makes it a promising treatment option across numerous medical disciplines.

The end-users of the cell therapy market can be categorized into two main segments: hospitals and clinics, and research institutes and laboratories. Hospitals and clinics play a crucial role in administering cell therapies to patients, while research institutes and laboratories focus on developing and testing new cell-based treatments.

Covid-19 Impact on the Global Cell Therapy Market:

The COVID-19 pandemic has had a significant impact on the cell therapy market. While the pandemic disrupted healthcare systems worldwide, it also highlighted the urgent need for innovative and effective treatments. In the initial stages of the pandemic, many clinical trials and research activities related to cell therapy were temporarily halted or delayed, as the focus shifted to combating the virus and ensuring patient safety. This disruption in research and development had a short-term negative impact on the cell therapy market.

However, as the pandemic progressed, the importance of cell therapy became more evident. Cell-based therapies, such as convalescent plasma therapy and mesenchymal stem cell therapy, were explored as potential treatments for COVID-19 patients. These therapies aimed to modulate the immune response, reduce inflammation, and promote tissue repair. The use of cell therapy in the context of COVID-19 generated renewed interest and accelerated research efforts in the field.

Moreover, the pandemic brought to light the vulnerabilities of traditional healthcare systems and the need for advanced therapies. This realization has led to increased investments in cell therapy research and development, as well as the adoption of supportive regulatory measures to expedite the development and approval of cell-based treatments. As a result, the long-term impact of the pandemic on the cell therapy market is expected to be positive, with a growing focus on advanced therapies and a greater recognition of their potential in addressing critical healthcare challenges.

Key Players of Global Cell Therapy Market Report-

Some major key players for the global Cell Therapy Market report cover prominent players like

• Novartis
• Gilead Sciences
• Johnson & Johnson
• Bristol-Myers Squibb
• Celgene Corporation
• Bluebird Bio
• Kite Pharma
• Fate Therapeutics
• Mesoblast
• Adaptimmune Therapeutics
• Takeda Pharmaceutical Company
• Astellas Pharma
• Celyad
• CRISPR Therapeutics
• Pluristem Therapeutics
• Cellectis
• MaxCyte
• Lonza Group
• Athersys
• Gamida Cell
• others

Global Cell Therapy Segmentation:-

By Cell Type:

• Stem Cell
• Bone Marrow
• Blood
• Umbilical Cord-Derived
• Adipose-Derived Stem Cell
• Others
• Non-stem Cell

By Therapy Type:

• Autologous
• Allogeneic

By Therapeutic Area:

• Malignancies
• Musculoskeletal Disorders
• Autoimmune Disorders
• Dermatology
• Others

By Technology:

• Viral Vector Technology
• Genome Editing Technology
• Somatic Cell Technology
• Cell Immortalization Technology
• Cell Plasticity Technology
• Three-dimensional Technology

By End-User:

• Hospitals
• Diagnostic centers
• Clinics
• Research institutes
• Regenerative medicine centers
• Others

Market Revenue Generation Model:

The revenue generation model for the cell therapy market typically involves a combination of factors. These include the sale of cell therapy products, such as genetically modified cells or stem cell-based therapies, to healthcare providers. Additionally, contract manufacturing services for cell therapy products, clinical trial collaborations with pharmaceutical companies, and licensing agreements also contribute to revenue generation in this market.

Supply Chain Analysis:

The supply chain model for the cell therapy market is complex and involves multiple stakeholders. It typically starts with the collection of cells from donors or patients, followed by processing and manufacturing in specialized facilities. Quality control and assurance are critical throughout the manufacturing process to ensure the safety and efficacy of the cell therapies. After manufacturing, the cell therapies are distributed to hospitals, clinics, and research institutes for administration to patients.

Value Chain Analysis:

The value chain model for the cell therapy market encompasses the entire lifecycle of cell therapy products. It starts with research and development efforts in academic and industry settings to discover and develop new cell-based treatments. This is followed by the manufacturing and production phase, where cell therapies are produced at scale. The therapies are then marketed and distributed to end users. Finally, patient access and outcomes are important aspects of the value chain, ensuring that the therapies reach the intended patients and deliver positive clinical results.

Market Drivers:

Increasing Prevalence of Chronic and Degenerative Diseases: The increasing prevalence of chronic and degenerative diseases is a significant driver for the cell therapy market. Conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders are on the rise globally, creating a growing patient population in need of effective treatments.

According to the International Agency for Research on Cancer (IARC), there were an estimated 19.3 million new cancer cases and 10 million cancer-related deaths worldwide in 2020. And the Alzheimer's Association states that Alzheimer's disease is the most common cause of dementia, affecting over 50 million people worldwide. Parkinson's disease affects an estimated 7 to 10 million people globally, according to the Parkinson's Foundation.

Cell therapy offers promising solutions by utilizing living cells to repair, regenerate, or replace damaged tissues and organs, addressing the unmet medical needs of these patients. The rising burden of these diseases drives the demand for innovative therapies like cell therapy, leading to increased research, development, and commercialization efforts in the field. Ultimately, the goal is to provide improved treatment options and better patient outcomes in the face of the growing disease burden.

Advancements in Regenerative Medicine: Regenerative medicine encompasses various technologies, such as stem cell research, tissue engineering, and gene editing, which have shown tremendous potential in developing innovative cell-based therapies. For example, advancements in gene editing and tissue engineering technology have endorsed the ex vivo remodeling of stem cells grown into 3D organoids and tissue structures for personalized applications.

These advancements enable scientists and researchers to manipulate and engineer cells to repair, replace, or regenerate damaged tissues and organs.  For example; Yescarta (Gilead Sciences) is another CAR T-cell therapy used for the treatment of certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphomaThe continuous progress in regenerative medicine fuels the development of novel cell therapies, expands treatment options for patients, and holds the promise of revolutionizing the field of medicine. By harnessing the regenerative capabilities of cells, researchers aim to address unmet medical needs and improve patient outcomes across a wide range of diseases and conditions.

Market Restraints:

Manufacturing and scale-up challenges pose significant restraints in the cell therapy market. The complex nature of cell therapy manufacturing, which involves growing, expanding, and manipulating living cells, presents technical and logistical difficulties. Maintaining consistent quality, ensuring product safety, and achieving scalability are major hurdles that impact the efficient and cost-effective production of cell therapies.

The need for specialized facilities, skilled personnel, and stringent quality control measures further adds to the challenges. These manufacturing and scale-up constraints can impede the timely delivery of cell therapies to patients and limit their widespread adoption in healthcare systems.

Market Opportunities:

Expansion into Rare Diseases and Orphan Indications: Cell therapy holds promise for treating rare diseases and orphan indications, where there is a significant unmet medical need. The ability of cell therapies to target specific molecular pathways or repair damaged tissues makes them attractive for addressing these niche markets.

Personalized Medicine Approach: Cell therapies can be tailored to individual patients, offering personalized medicine solutions. This approach utilizes patient-specific cells or genetically modified cells to optimize treatment outcomes, potentially leading to higher efficacy and reduced side effects.

Combination Therapies and Immunotherapies: There is an opportunity to explore combination therapies, such as combining cell therapies with immune checkpoint inhibitors or other modalities, to enhance treatment effectiveness. Additionally, the field of cancer immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, continues to evolve with ongoing research and development.

Market Trends:

Product and Technology Development Trends:

Development of Off-the-Shelf Products: Efforts are underway to develop off-the-shelf cell therapy products that can be readily available for patients, eliminating the need for personalized manufacturing and reducing costs and manufacturing complexities.

Gene-Modified Cell Therapies: Gene editing technologies, such as CRISPR-Cas9, are being used to genetically modify cells, enabling precise modifications and enhancing therapeutic properties of cell therapies. This trend is expected to continue, allowing for more targeted and effective treatments.

Customer Trends:

Focus on Safety and Efficacy: Customers, including patients and healthcare providers, place significant importance on the safety and efficacy of cell therapies. Regulatory approvals and clinical trial data demonstrating positive outcomes play a crucial role in customer decision-making and acceptance of cell therapies.

Access to Affordable Cell Therapies: There is a growing focus on ensuring affordability and accessibility of cell therapies. Efforts to optimize manufacturing processes, reduce costs, and establish reimbursement mechanisms aim to address these concerns and expand patient access to these treatments.

Market Competition Nature:

Competition in the cell therapy market is intensifying as more companies enter the space and advancements continue to drive innovation. Several key players are vying for market share and striving to establish their position in this rapidly evolving field. Here are some highlights of past strategies, along with examples, and potential future strategies in the cell therapy market:

Past Strategies:

Acquisition and Partnerships: Companies have pursued acquisitions and partnerships to strengthen their capabilities, expand their product portfolios, and enhance their research and development efforts. For example, Gilead Sciences acquired Kite Pharma in 2017, gaining access to their CAR-T cell therapy platform and expanding their presence in the cell therapy market.

Focus on Pipeline Development: Companies have heavily invested in research and development, with a focus on advancing their pipeline of cell therapies across various therapeutic areas. Bluebird Bio, for instance, has been developing gene and cell therapies for rare genetic diseases, with multiple candidates in clinical trials.

Establishing Manufacturing and Supply Chain Infrastructure: Building robust manufacturing and supply chain capabilities has been a key strategy to meet the increasing demand for cell therapies. Companies like Novartis have made substantial investments in developing state-of-the-art manufacturing facilities to ensure scalable and reliable production of their cell therapies.

Future Strategies:

Portfolio Diversification: As the cell therapy market expands, companies may look to diversify their product portfolios by targeting different therapeutic areas or exploring combination therapies. This strategy can help address a broader range of diseases and maximize market opportunities.

Advanced Manufacturing Technologies: Investing in advanced manufacturing technologies, such as automation, closed-system processes, and 3D bioprinting, can enable more efficient and cost-effective production of cell therapies. Companies may adopt these technologies to enhance scalability, reduce manufacturing complexities, and improve cost-effectiveness.

Global Expansion: With the cell therapy market expanding beyond traditional markets, companies may explore opportunities for global expansion by entering new geographical regions, forging partnerships with local stakeholders, and adapting their strategies to different regulatory environments.

Geography Analysis:

North America:

North America has been at the forefront of research and development in this field, with numerous academic institutions, biotechnology companies, and clinical research organizations actively engaged in advancing cell-based therapies. The United States, in particular, plays a pivotal role in driving the growth of the market in North America, owing to its robust healthcare infrastructure, supportive regulatory environment, and substantial investments in research and development.

North America has seen a surge in the number of clinical trials and commercialization efforts for cell therapies across various indications, including oncology, cardiovascular diseases, neurological disorders, and autoimmune conditions. For instance; in february 2020, Catalent Inc, a US-based company, acquired MaSTherCell, a cell therapy manufacturing specialist located in Gosselies, Belgium, for $315 million. In April 2022, Catalent further expanded its capabilities by acquiring a commercial-scale cell therapy development and manufacturing facility in Princeton, New Jersey.

The region's strong emphasis on innovation and collaboration has fostered the establishment of advanced manufacturing facilities, specialized bioprocessing capabilities, and dedicated cell therapy centers. This infrastructure enables the efficient production, processing, and delivery of cell-based therapies to patients.

For instance; in May 2022, ViaCyte, Inc. partnered with SQZ Biotechnologies to develop and commercialize the search-use-only (RUO) microfluidic intracellular delivery system. The partnership will allow both the market players to present new cell engineering data in hematopoietic stem cells using mRNA.

Europe's Cell Therapy Market is Experiencing Significant Growth and is Poised to Play a Crucial Role in Advancing the Field of Regenerative Medicine:

The region has a well-established healthcare infrastructure, strong regulatory frameworks, and a robust scientific community, which have contributed to the development and adoption of innovative cell therapies. For example; in 2022, several European nations allocated a significant portion of their GDP to healthcare, such as Germany (12.8%), France (12.2%), and the United Kingdom (10%). European countries have been actively investing in cell therapy research, fostering collaborations between academia, industry, and healthcare providers.

One of the key factors driving the growth of the cell therapy market in Europe is the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions. Cell therapies offer a promising avenue for developing targeted treatments that can address the underlying causes of these diseases and provide long-term benefits to patients.

European countries have also been at the forefront of regulatory developments to support the safe and effective implementation of cell therapies. Regulatory bodies such as the European Medicines Agency (EMA) have established guidelines and frameworks to assess the quality, safety, and efficacy of cell-based products. This regulatory environment fosters innovation while ensuring patient safety and quality standards.

The European Medicines Agency began an accelerated review of EtranaDez for possible approval as a first gene therapy for hemophilia B in March 2022, with a decision likely by early fall. uniQure and CSL Behring expect to soon file a similar approval request with the U.S. Food and Drug Administration (FDA).

By Regional & Country Level:

• North America

  • US.
  • Canada

• Europe

  • UK.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa 

Key Benefits of Global Cell Therapy Market Report–

• Global Cell Therapy Market report covers in-depth historical and forecast analysis.
• Global Cell Therapy Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Cell Therapy Market report helps to identify opportunities in the marketplace.
• Global Cell Therapy Market report covers extensive analysis of emerging trends and competitive landscape.